| Dr Deepthi Rimmalapudi, MD | |
|
915 Goethals Dr, Richland, WA 99352-3527 | |
| (509) 547-2204 | |
| (509) 542-8836 |
| Full Name | Dr Deepthi Rimmalapudi |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 11 Years |
| Location | 915 Goethals Dr, Richland, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1417308693 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | MD61125553 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kadlec Regional Medical Center | Richland, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tri-cities Community Health | 4183517469 | 19 |
News Archive
Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.
This new study, based on a large, nationwide sample, suggests a critical flaw in that previous research, said Aaron Wichman, lead author of the new study and a teaching fellow in psychology at Ohio State University.
Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.
NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.
› Verified 9 days ago
| Entity Name | Tri-cities Community Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861698987 PECOS PAC ID: 4183517469 Enrollment ID: O20040203000209 |
News Archive
Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.
This new study, based on a large, nationwide sample, suggests a critical flaw in that previous research, said Aaron Wichman, lead author of the new study and a teaching fellow in psychology at Ohio State University.
Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.
NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Deepthi Rimmalapudi, MD Po Box 1452, Pasco, WA 99301-1223 Ph: (509) 547-2204 | Dr Deepthi Rimmalapudi, MD 915 Goethals Dr, Richland, WA 99352-3527 Ph: (509) 547-2204 |
News Archive
Zalicus Inc. today reported financial results for the third quarter ended September 30, 2011.
This new study, based on a large, nationwide sample, suggests a critical flaw in that previous research, said Aaron Wichman, lead author of the new study and a teaching fellow in psychology at Ohio State University.
Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.
NeuroDerm, Ltd. announced today the enrollment of the first group of patients in its Phase I/II clinical trial of ND0611, a new patch for the treatment of Parkinson's disease.
› Verified 9 days ago
Kalavati Paila, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd., Richland, WA 99352 Phone: 509-946-4611 Fax: 509-942-2185 | |
Dr. Braghadheeswar Thyagarajan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-942-2648 Fax: 509-942-2812 | |
Ziga Tretjak, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 780 Swift Blvd, Suite 270, Kadlec Clinic, Gastroenterology, Richland, WA 99352 Phone: 509-942-3627 Fax: 509-943-3280 | |
Dr. Caleb Haws, D.O. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-942-3627 Fax: 509-627-2983 | |
Nazar Hafiz, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1270 Lee Blvd Ste A, Richland, WA 99352 Phone: 509-942-3180 Fax: 509-943-9722 | |
Arnulfo T Deray, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 888 Swift Blvd, Richland, WA 99352 Phone: 509-946-4611 Fax: 509-942-2185 | |
Munish Kumar Kannabhiran, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1100 Goethals Dr Ste E, Richland, WA 99352 Phone: 509-942-3272 Fax: 509-942-3273 |